12 Jun 2022
Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients
Author: admintech | Filed under: Press ReleaseGracell also presented data on GC012F for treatment of B-NHL and allogeneic TruUCAR-candidate GC502 for treatment of B-ALL Management to host clinical update call on Monday, June 13, at 8:00AM ET SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, June 12, 2022 /PRNewswire/ — Gracell…